Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
41.3M
-
Shares change
-
+8.21M
-
Total reported value, excl. options
-
$1.29B
-
Value change
-
+$254M
-
Number of buys
-
74
-
Number of sells
-
-14
-
Price
-
$31.09
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q1 2021
104 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2021.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.3M shares
of 77.1M outstanding shares and own 53.6% of the company stock.
Largest 10 shareholders include The Column Group LLC (5.38M shares), TRV GP III, LLC (4.51M shares), Redmile Group, LLC (3.31M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.09M shares), BAKER BROS. ADVISORS LP (2.45M shares), EcoR1 Capital, LLC (2.02M shares), BlackRock Inc. (1.82M shares), STATE STREET CORP (1.38M shares), WELLINGTON MANAGEMENT GROUP LLP (1.36M shares), and Bain Capital Life Sciences Investors, LLC (1.28M shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.